DGAP-Adhoc: Dermapharm Holding SE raises EBITDA forecast for the full year 2021

2021. december 16., csütörtök, 12:08

DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Change in Forecast

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

16-Dec-2021 / 12:08 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)

No. 596/2014 on market abuse, as amended

(Market Abuse Regulation - MAR)

Dermapharm Holding SE raises EBITDA forecast for the full year 2021

Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA1 to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year.

1 EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020).

>End of the Ad hoc announcement<


Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

E-Mail: ir@dermapharm.com

16-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1258883

End of Announcement DGAP News Service

1258883  16-Dec-2021 CET/CEST

Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.